Effect of intracoronary nicardipine on methylergonovine-induced coronary artery spasm in patients with variant angina.

Abstract

In a double-blind, randomized placebo controlled study, the effect of intracoronary (IC) nicardipine (0.4 mg) on methylergonovine (0.4 mg) induced coronary artery spasm was assessed in 16 patients with a history of variant angina. Reversal of the methylergonovine-induced coronary artery spasm was observed in 100% of patients treated with IC nicardipine and 25% of patients treated with placebo (p less than 0.01). There were no significant differences between the nicardipine and placebo treatment groups with respect to heart rate, blood pressure, proportion of patients experiencing chest pain or ST segment changes. These findings demonstrate that IC nicardipine is safe and could be effective in the reversal of coronary artery spasm in patients with variant angina.

• Authors: M E Bertrand, J M La Blanche, P Hudon, S Grandy, P Turlapaty, A R Laddu
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 27 Issue 1 Pg. 39-43 (Jan 1989) ISSN: 0174-4879 [Print] Germany
• PMID: 2744905 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Nicardipine
• Methylergonovine

Topics

• Angina Pectoris, Variant (drug therapy)
• Coronary Vasospasm (chemically induced, prevention & control)
• Coronary Vessels (metabolism)
• Double-Blind Method
• Electrocardiography
• Humans
• Methylergonovine
• Middle Aged
• Nicardipine (administration & dosage, pharmacology)
• Random Allocation